Radiobiology

Cosmic Shielding Corporation raises $1 million in pre-seed round to enable a permanent human presence in space

Retrieved on: 
Wednesday, May 5, 2021
Radiation, Human spaceflight, Applied sciences, Space medicine, Physical sciences, Radiobiology, Health threat from cosmic rays, Ionizing radiation, Electromagnetic shielding, Space suit

b'ATLANTA, May 5, 2021 /PRNewswire/ --Today Cosmic Shielding Corporation (CSC), the leading space technology company for multifunctional radiation solutions, announced it has closed a $1 million pre-seed capital raise.

Key Points: 
  • b'ATLANTA, May 5, 2021 /PRNewswire/ --Today Cosmic Shielding Corporation (CSC), the leading space technology company for multifunctional radiation solutions, announced it has closed a $1 million pre-seed capital raise.
  • The funding will help the company continue to grow its team and accelerate product testing of its radiation shielding composites.
  • "The future of space travel will rely on spacecraft and spacesuits that can effectively shield humans and hardware from the risks of space radiation.
  • By designing these with cutting edge composites built for the harsh environment of space, we can enable humanity to become a truly space faring civilization.

NorthStar Medical Radioisotopes to Present at the Emerging Medtech Summit 2021

Retrieved on: 
Tuesday, May 4, 2021
Oncology, Health, Medical devices, Radiology, Pharmaceutical, Cardiology, Biotechnology, Health sciences, Medicine, Radiopharmaceuticals, Physical sciences, Medicinal radiochemistry, Medicinal chemistry, Radiation therapy, Radiobiology, Radiopharmacology, Northstar, Medtech

b'NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will present a corporate overview at the Emerging Medtech Summit 2021, on May 12, 2021 at 3:57 p.m. PT in Dana Point, Ca.

Key Points: 
  • b'NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will present a corporate overview at the Emerging Medtech Summit 2021, on May 12, 2021 at 3:57 p.m. PT in Dana Point, Ca.
  • The Emerging Medtech Summit 2021 brings together top strategists, investors and innovators driving the future of healthcare.
  • Information about the Summit is available here .\nStephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will provide an update on NorthStar, including its progress in advancing U.S. radioisotope production and its expanding portfolio.
  • Therapeutic radioisotopes are increasingly important cancer treatment options, and NorthStar is developing commercial-scale production technologies to meet high demand for their use in ongoing clinical trials by multiple pharmaceutical companies.

Reminder: C-RAD Web Presentation Interim Report Q1 2021 and AGM speech

Retrieved on: 
Tuesday, May 4, 2021
Radiobiology, Radiation, Ionizing radiation, Nuclear physics, Radiation protection, Radioactivity, Medical physics, Absorbed dose, Radiation therapy, Radiation exposure, Rad, Rad

b"After the registration, you will receive a confirmation via email.\nA recording of the presentation will be made accessible on the C-RAD website after the presentation.\nC-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure.

Key Points: 
  • b"After the registration, you will receive a confirmation via email.\nA recording of the presentation will be made accessible on the C-RAD website after the presentation.\nC-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure.
  • Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy.
  • C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.\nC-RAD.
  • Inspiring excellence in cancer treatment.\nC-RAD AB is listed on NASDAQ Stockholm.\n"

Cabaletta Bio Reports Acute Safety Data from the First Dose Cohort in DesCAARTes™ Trial

Retrieved on: 
Monday, May 3, 2021
Academic disciplines, Radiation protection, Radiobiology, Military of ancient Rome, Absorbed dose, Cohort, Dose, Applied mathematics

Infusions are planned to initiate following the third patient in the first dose cohort completing the 28-day monitoring period without any DLTs.

Key Points: 
  • Infusions are planned to initiate following the third patient in the first dose cohort completing the 28-day monitoring period without any DLTs.
  • Cabaletta expects to announce acute safety data for the second and third cohorts in the third and fourth quarters of 2021, respectively.
  • Topline data on target engagement from the first cohort are anticipated during the second half of 2021.
  • The study consists of three parts: 1) dose escalation, 2) dose consolidation, and 3) cohort expansion at the final selected dose and schedule.

Accuray Customers Achieve Top Scores in AAPM MArkerless Lung Target Tracking CHallenge (MATCH) Using Synchrony® Technology on the Radixact® and CyberKnife® Systems

Retrieved on: 
Thursday, April 29, 2021
Medicine, Clinical medicine, Medical physics, Neurosurgery, Radiobiology, Cyberknife, Radiation therapy, Image-guided radiation therapy, Tomotherapy

b'SUNNYVALE, Calif., April 29, 2021 /PRNewswire/ --Accuray Incorporated (NASDAQ: ARAY) announced today that Accuray customers took the top two positions in the MArkerless Lung Target Tracking CHallenge (MATCH) experimental branch using the Accuray Synchrony Lung Tracking with Respiratory Modeling on the Radixact next-generation TomoTherapy platform, and CyberKnife System , respectively.

Key Points: 
  • b'SUNNYVALE, Calif., April 29, 2021 /PRNewswire/ --Accuray Incorporated (NASDAQ: ARAY) announced today that Accuray customers took the top two positions in the MArkerless Lung Target Tracking CHallenge (MATCH) experimental branch using the Accuray Synchrony Lung Tracking with Respiratory Modeling on the Radixact next-generation TomoTherapy platform, and CyberKnife System , respectively.
  • "As part of the process, more than 200 image-guided radiation therapy (IMRT) QA plans were delivered, with the majority being markerless (fiducial-free) lung tumor plans.
  • "Synchrony on the Radixact and CyberKnife Systems enables highly accurate and efficient delivery of (ultra) hypofractionated radiation therapy, increasingly being used to treat a range of lung tumors.
  • "\nAccuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible.

Galera Announces Updated Data from its Randomized, Multicenter, Placebo-Controlled Trial in Patients with Pancreatic Cancer

Retrieved on: 
Wednesday, April 28, 2021
Medical physics, Radiobiology, Radiation therapy, Radioactivity, Nuclear physics, Physical sciences, Medicine

29% of patients in the treatment arm achieved a 30% or greater response (partial response) compared to 11% of patients in the placebo arm.

Key Points: 
  • 29% of patients in the treatment arm achieved a 30% or greater response (partial response) compared to 11% of patients in the placebo arm.
  • Positive results were also observed in local tumor control, time to metastases and progression-free survival.
  • A pilot Phase 1/2 trial of avasopasem in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer (LAPC) has completed enrollment and reported results, with follow-up ongoing.
  • Galera also intends to initiate the GRECO-2 Phase 2b trial of GC4711 in combination with SBRT in patients with LAPC.

Accuray Appoints Jean-Philippe Pignol, M.D., Ph.D. as Chief Medical & Technology Officer

Retrieved on: 
Monday, April 26, 2021
Radiobiology, Radiation therapy, Radioactivity, Physical sciences, Natural sciences, Physics

b'SUNNYVALE, Calif., April 26, 2021 /PRNewswire/ --Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Jean-Philippe Pignol, M.D., Ph.D. as its chief medical & technology officer, effective as of April 15, 2021.

Key Points: 
  • b'SUNNYVALE, Calif., April 26, 2021 /PRNewswire/ --Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Jean-Philippe Pignol, M.D., Ph.D. as its chief medical & technology officer, effective as of April 15, 2021.
  • For the past three years, he has served as professor and department head of the department of radiation oncology at Dalhousie University in Halifax, Canada.
  • With the right technology, this treatment modality helps enable patients to not just live longer, but to live better and to thrive," said Jean-Philippe Pignol, M.D., Ph.D., chief medical & technology officer at Accuray.
  • I have long been very impressed by Accuray and the very innovative radiation therapy delivery systems its global team has brought to market.

The NOBLE Registry – An International Collaboration to Develop iPSMA SPECT Imaging for Prostate Cancer

Retrieved on: 
Tuesday, April 20, 2021
Branches of biology, Medical physics, Medicine, Neuroimaging, Medical specialties, Radiobiology, Radiation therapy, Glutamate carboxypeptidase II, Peptidase, Single-photon emission computed tomography, Emission computed tomography, Positron emission tomography

The NOBLE (Nobody Left Behind) Registry aims to demonstrate that PSMA single photon emission computed tomography (PSMA SPECT), a diagnostic imaging technology widely available in healthcare facilities throughout the world,4 is a cost-effective and viable alternative.

Key Points: 
  • The NOBLE (Nobody Left Behind) Registry aims to demonstrate that PSMA single photon emission computed tomography (PSMA SPECT), a diagnostic imaging technology widely available in healthcare facilities throughout the world,4 is a cost-effective and viable alternative.
  • \xe2\x80\x9cHowever, millions of men do not have access to PET imaging.
  • For this reason, it is our aspiration to develop a powerful, affordable, and widely available alternative imaging tool by using iPSMA SPECT technology.\xe2\x80\x9d\n\xe2\x80\x9cIntroducing PSMA has been difficult and exciting for the team at Ibadan.
  • When I think of the opportunities for prostate cancer research and management without PET, I am motivated to get past the challenges.

222-nm Far UVC Cancer Risk With Unfiltered Far UV-C 222 Excimer (KrCl) Krypton Chloride Excilamps Claims Far-UVC Test Card Manufacture QuantaDose

Retrieved on: 
Friday, April 23, 2021
Hygiene, Radiobiology, Sterilization, Ultraviolet germicidal irradiation, Ultraviolet radiation, MJ, Disinfectant, Academic disciplines, Physical sciences, Health

The light would also disinfect your skin before your hands spread germs to your face.

Key Points: 
  • The light would also disinfect your skin before your hands spread germs to your face.
  • This scenario is already popping up in businesses worldwide, including right here in the USA.
  • USA 22 mJ/cm2 EU 30 mJ/cm2\nDownload it here Excel Doc.
  • Different levels of professional expertise are required depending on the category of product offering.\nA professional assessment is always required for safe AP-UVGI and effective Far-UV deployment.\n'

C-RAD Web Presentation Interim Report Q1 2021 and AGM speech

Retrieved on: 
Friday, April 23, 2021
Radiobiology, Radiation, Ionizing radiation, Nuclear physics, Radiation protection, Radioactivity, Medical physics, Absorbed dose, Radiation therapy, Radiation exposure, Rad, Rad

b"After the registration, you will receive a confirmation via email.\nA recording of the presentation will be made accessible on the C-RAD website after the presentation.\nC-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure.

Key Points: 
  • b"After the registration, you will receive a confirmation via email.\nA recording of the presentation will be made accessible on the C-RAD website after the presentation.\nC-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure.
  • Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy.
  • C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.\nC-RAD.
  • Inspiring excellence in cancer treatment.\nC-RAD AB is listed on NASDAQ Stockholm.\n"